Literature DB >> 29752326

Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.

Carlos H Barcenas, Maryam N Shafaee, Arup K Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K Murthy, Ashley H Woodson, Banu Arun.   

Abstract

Background: Inherited BRCA gene mutations (pathogenic variants) cause 10% of breast cancers. BRCA pathogenic variants predispose carriers to triple-negative breast cancer (TNBC); around 30% of patients with TNBC carry BRCA pathogenic variants. The 2018 NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian recommend genetic counseling referrals for patients with TNBC diagnosed at age ≤60 years. This study sought to describe genetic counseling referral patterns among long-term TNBC survivors at The University of Texas MD Anderson Cancer Center.
Methods: This single-institution retrospective analysis of female long-term (disease-free for ≥5 years) TNBC survivors sought to determine the rate of genetic counseling referral among patients diagnosed at age ≤60 years between 1992 and 2008. Patients who underwent treatment and surveillance visits at our institution and were followed until 2017 were included. We collected BRCA pathogenic variant status among tested patients. Descriptive statistical methods and a univariate analysis were used to identify patient characteristics associated with genetic counseling referral.
Results: We identified 646 female long-term TNBC survivors with a median age at diagnosis of 47 years. Of these, 245 (38%) received a recommendation for a genetic counseling referral. Among those referred, 156 (64%) underwent genetic testing, and 35% of those tested had BRCA pathogenic variants. Interestingly, among those referred, 20% declined genetic testing. The rate of genetic referrals improved over time, from 25% among TNBC survivors whose last surveillance visit was between 2011 and 2013 to 100% among those whose last surveillance visit was between 2014 or later. Younger age and premenopausal status at diagnosis and a family history of breast or ovarian cancer were associated with an increased rate of referral for genetic counseling. Conclusions: Among long-term TNBC survivors, the rate of referral to genetic counseling increased over time, and among those tested, 35% carried a BRCA pathogenic variant. Survivorship care provides an excellent opportunity to refer eligible patients for genetic counseling.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2018        PMID: 29752326      PMCID: PMC5978679          DOI: 10.6004/jnccn.2018.7002

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  27 in total

1.  Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.

Authors:  Soley Bayraktar; Angelica M Gutierrez-Barrera; Diane Liu; Tunc Tasbas; Ugur Akar; Jennifer K Litton; E Lin; Constance T Albarracin; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun
Journal:  Breast Cancer Res Treat       Date:  2011-08-10       Impact factor: 4.872

2.  Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.

Authors:  Kathryn J Ruddy; Betsy C Risendal; Judy E Garber; Ann H Partridge
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

3.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

Authors:  Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

4.  Keeping pace with the times--the Genetic Information Nondiscrimination Act of 2008.

Authors:  Kathy L Hudson; M K Holohan; Francis S Collins
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

5.  Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.

Authors:  Anne Marie McCarthy; Mirar Bristol; Susan M Domchek; Peter W Groeneveld; Younji Kim; U Nkiru Motanya; Judy A Shea; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2016-05-09       Impact factor: 44.544

6.  American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Authors:  Karen H Lu; Marie E Wood; Molly Daniels; Cathy Burke; James Ford; Noah D Kauff; Wendy Kohlmann; Noralane M Lindor; Therese M Mulvey; Linda Robinson; Wendy S Rubinstein; Elena M Stoffel; Carrie Snyder; Sapna Syngal; Janette K Merrill; Dana Swartzberg Wollins; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

7.  Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Authors:  Fergus J Couch; Katherine L Nathanson; Kenneth Offit
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

8.  Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer.

Authors:  Kathryn J Schlich-Bakker; Herman F J ten Kroode; Carla C Wárlám-Rodenhuis; Jan van den Bout; Margreet G E M Ausems
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

9.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Authors:  Deann P Atchley; Constance T Albarracin; Adriana Lopez; Vicente Valero; Christopher I Amos; Ana Maria Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

10.  Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .

Authors:  Allison W Kurian; Kent A Griffith; Ann S Hamilton; Kevin C Ward; Monica Morrow; Steven J Katz; Reshma Jagsi
Journal:  JAMA       Date:  2017-02-07       Impact factor: 157.335

View more
  3 in total

1.  Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.

Authors:  Arnethea L Sutton; Alejandra Hurtado-de-Mendoza; John Quillin; Lisa Rubinsak; Sarah M Temkin; Tamas Gal; Vanessa B Sheppard
Journal:  J Womens Health (Larchmt)       Date:  2019-11-27       Impact factor: 2.681

Review 2.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer.

Authors:  Laura Cortesi; Hope S Rugo; Christian Jackisch
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

3.  Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.

Authors:  Robert S Miller; Stella Mokiou; Aliki Taylor; Ping Sun; Katherine Baria
Journal:  Breast Cancer Res Treat       Date:  2022-02-22       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.